APREA THERAPEUTICS INC (APRE) Stock Analyst Earnings Estimates
NASDAQ:APRE - Nasdaq - US03836J2015 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 583.2K | 1.503M 157.65% | 82.62K -94.50% | -100.00% | 30.195M | 67.805M 124.56% | 118.92M 75.39% | 193.65M 62.84% | 186.21M -3.84% | 326.77M 75.48% | ||
| EBITDA YoY % growth | -113.39M -202.86% | -15.465M 86.36% | -14.297M 7.55% | -17.85M -24.85% | -20.196M -13.14% | -24.582M -21.72% | -24.684M -0.41% | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -113.39M -202.78% | -15.472M 86.36% | -14.32M 7.45% | -18.993M -32.64% | -24.655M -29.81% | -6.288M 74.49% | 24.668M 492.28% | 62.44M 153.12% | 113.66M 82.03% | 145.76M 28.24% | 271.82M 86.48% | |
| Operating Margin | N/A | -2,652.95% | -952.99% | -22,988.89% | N/A | -20.83% | 36.38% | 52.51% | 58.69% | 78.28% | 83.18% | |
| EPS YoY % growth | -30.12 -14.70% | -3.99 86.75% | -2.38 40.35% | -1.48 37.71% | -1.30 12.39% | -0.64 51.05% | 1.22 292.51% | 2.35 91.67% | 3.32 41.30% | 4.81 45.23% | N/A |
All data in USD
| Q3 / 25 | Q4 / 25 | |
|---|---|---|
| EPS Q2Q % growth | -0.35 46.05% | -0.35 28.18% |
| Revenue Q2Q % growth | -100.00% | -100.00% |
| EBITDA Q2Q % growth | N/A | N/A |
| EBIT Q2Q % growth | -4.306M -5.11% | -4.562M -41.43% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.53 8.62% | -0.76 | 0.23 | 30.25% |
| Q1 2025 Q2Q % growth | -31.69% | -0.88 | % | |
| Q4 2024 Q2Q % growth | -0.49 46.74% | -0.70 | 0.21 | 30.04% |
| Q3 2024 Q2Q % growth | -0.64 25.58% | -0.76 | 0.12 | 15.78% |
| Q2 2024 Q2Q % growth | -0.58 33.33% | -0.65 | 0.07 | 10.45% |
| Q1 2024 Q2Q % growth | -0.67 50.00% | -0.79 | 0.12 | 15.41% |
| Q4 2023 Q2Q % growth | -0.92 | -0.79 | -0.13 | -16.63% |
| Q3 2023 Q2Q % growth | -0.86 64.17% | -1.19 | 0.33 | 27.54% |
| Q2 2023 Q2Q % growth | -0.87 95.56% | -1.45 | 0.58 | 40.14% |
| Q1 2023 Q2Q % growth | -1.34 81.39% | -1.54 | 0.20 | 12.71% |
| Q4 2022 Q2Q % growth | -0.92 87.22% | -3.14 | 2.22 | 70.72% |
| Q3 2022 Q2Q % growth | -2.40 73.33% | -5.61 | 3.21 | 57.22% |
| Q2 2022 Q2Q % growth | -19.60 -104.17% | -7.65 | -11.95 | -156.21% |
| Q1 2022 Q2Q % growth | -7.20 -1,465.22% | -7.75 | 0.55 | 7.12% |
| Q4 2021 Q2Q % growth | -7.20 -886.30% | -8.98 | 1.78 | 19.79% |
| Q3 2021 Q2Q % growth | -9.00 -1,451.72% | -9.23 | 0.23 | 2.50% |
| Q2 2021 Q2Q % growth | -9.60 -1,130.77% | -9.54 | -0.06 | -0.66% |
| Q1 2021 Q2Q % growth | -0.46 -2.22% | -0.50 | 0.04 | 8.43% |
| Q4 2020 Q2Q % growth | -0.73 -14.06% | -0.66 | -0.07 | -11.39% |
| Q3 2020 Q2Q % growth | -0.58 89.04% | -0.78 | 0.20 | 25.18% |
| Q2 2020 Q2Q % growth | -0.78 | -0.61 | -0.17 | -26.92% |
| Q1 2020 Q2Q % growth | -0.45 | -0.58 | 0.13 | 22.26% |
| Q4 2019 Q2Q % growth | -0.64 | -0.41 | -0.23 | -56.86% |
| Q3 2019 Q2Q % growth | -5.29 | -4.02 | -1.27 | -31.52% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | 120K -78.65% | 120K | % | |
| Q1 2025 Q2Q % growth | 162.5K -57.35% | 162.5K | % | |
| Q4 2024 Q2Q % growth | 206K 1,371.43% | 170.003K | 35.997K | 21.17% |
| Q3 2024 Q2Q % growth | 354.62K 11.17% | 229.5K | 125.12K | 54.52% |
| Q2 2024 Q2Q % growth | 562K 124.80% | 51K | 511K | 1,001.96% |
| Q4 2023 Q2Q % growth | 14K | 112.2K | -98.2K | -87.52% |
| Q3 2023 Q2Q % growth | 319K | 84.997K | 234.003K | 275.31% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | -5.97% | 0% | 4.39% |
| Revenue | N/A | N/A | -87.61% | -91% |